MedTrace Logo

Kaletra and Viread in Antiretroviral Naïve Patients

NCT00679926 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-12-04

Study results available
· View outcomes & findings →

Summary

Once daily antiretroviral therapy with Viread (tenofovir DF, 300mg) plus Kaletra (LPV/r, 800mg/200mg) will be effective in suppressing and maintaining suppression of HIV RNA to \<50 copies/ml in antiretroviral naïve patients through 48 weeks of therapy.

Conditions

  • HIV Infections

Interventions

DRUG

Once daily

Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Oklahoma State University Center for Health Sciences

    lead OTHER

Principal Investigators

  • Damon Baker, D.O. · Oklahoma State University Center for Health Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00679926 on ClinicalTrials.gov